BTIG Research lowered shares of TiGenix – American Depositary Shares (NASDAQ:TIG) from a buy rating to a neutral rating in a research note published on Tuesday morning. The analysts noted that the move was a valuation call.

Several other brokerages have also recently weighed in on TIG. Canaccord Genuity restated a buy rating and set a $30.00 target price (up from $22.00) on shares of TiGenix – American Depositary Shares in a report on Wednesday, September 20th. Zacks Investment Research cut TiGenix – American Depositary Shares from a hold rating to a sell rating in a report on Saturday, October 21st. Finally, BidaskClub upgraded TiGenix – American Depositary Shares from a strong sell rating to a sell rating in a report on Wednesday, December 27th.

Shares of TiGenix – American Depositary Shares (NASDAQ:TIG) traded down $0.25 during mid-day trading on Tuesday, reaching $41.94. The company had a trading volume of 1,288 shares, compared to its average volume of 22,238. TiGenix – American Depositary Shares has a 52 week low of $14.30 and a 52 week high of $42.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.37 and a quick ratio of 1.36.

A hedge fund recently bought a new stake in TiGenix – American Depositary Shares stock. EAM Investors LLC bought a new stake in shares of TiGenix – American Depositary Shares (NASDAQ:TIG) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned 1.20% of TiGenix – American Depositary Shares at the end of the most recent reporting period. 5.31% of the stock is currently owned by institutional investors.

WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/19/tigenix-american-depositary-shares-tig-rating-lowered-to-neutral-at-btig-research.html.

About TiGenix – American Depositary Shares

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.